Drug discovery company Nimbus Therapeutics has partnered with Eli Lilly to develop a novel oral treatment for obesity and other metabolic diseases.  The companies aim to apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery programme addressing a significant unmet need in obesity.  This latest collaboration follows a previous partnership between […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!